- 1
- 2
Mr. Tabuni Abdul
Novodiax pioneered a 10-minute ihcDirectTM IHC detection for frozen section technology, which significantly saves time and reduces reagent consumption and costs with easy to use by reducing steps from traditional protocols. This innovated technology has removed many of the time constraining barriers that once prevented application of IHC stains in intraoperative diagnosis and Mohs surgery labs.
Novodiax also provides multiplex IHC detection which accelerates turnaround time, increases instrument productivity and reduces reagent consumption.
In summary Novodiax enjoys the following major strength
1- Novodiax currently offers a 10 min IHC product line that can be used for intraoperative evaluation of frozen tissues and for Rapid On-Site Evaluation (ROSE) of biopsy specimens.
2- Novodiax will launch in Q4 2020 an advanced automation system including a rapid compact IHC stainer and a superfast FFPE tissue pre-treatment device along with tens of ihcDirect® IHC reagents. This affordable system is a perfect solution for any situation where a rapid turnaround time is needed, such as, the rush cases using FFPE tissues in large medical centers. Our 10 min intraoperative and ROSE protocols will be available on the system too.
3- Novodiax products have already been optimized for Leica staining instruments and can be optimized for all automated staining platforms in the market.
4- The rapid turnaround time of Novodiax’s reagents and instruments offers a natural advantage for multiplex applications.
Novodiax
Director of Business DevelopmentNishimura Akira
In addition, Luye has its own biosimilar business (novel antibodies, prolia, xgeva, eylea, avastin, opdivo, trulicity, consentyx, zaltrap, CAR-T); Established in 2013, Boan Biotech is a fully-integrated biopharmaceutical company, specializing in the research & development, manufacturing and commercialization of therapeutic antibodies, which are mainly focused on key therapeutic areas such as oncology, diabetes and immunological diseases.
Luye Pharma (HK2186)
Senior BD ManagerDr. Ameet Ambarkhane
Based Singapore, to partner drug development for US/EU/ASEAN market. Founder background - Pharmacist background with PHD, School of Pharmacy London, UK - Worked in Early drug discover and development @ Novartis-UK , commercial side Manufacturing science and technology MS&T in Novartis - Singapore and - Global technical operations -GTO, MSD - Singapore; Drug Device combination products. - Involved in successful filing of several INDs applied the concepts to drug development in a virtual small Biotech, to prepare for Phase 3 clinical trials Partnering objectives - Partner with likeminded companies to address the challenges posed by Covid-19 pandemic - Entrepreneurship, Start-ups, Joint ventures, Fundraising Primary area of expertise Drug Development, IND, NDA, Process validation, CMC, Technology transfer, Digital medicines, Digital Therapies, Entrepreneurship
Covate Pharma
DirectorMr. Andre Andre
Mara Phytotechnology Solutions
CEOAyla Annac
With an increasingly aging population with chronic diseases such as diabetes, heart failure is an urgent and critical challenge without an effective solution. There have been no successful phase III trials in worsening chronic heart failure or heart failure with preserved ejection fraction (HFpEF). Large clinical trials required for the heart failure trials have been the bottleneck. There is clear evidence showing that genetic factors drive heart failure development. Our mission is to cure heart failure one gene at a time.
We have leveraged our advanced artificial intelligence integrated breakthrough in precision medicine discovery platform using patient-derived human micro heart on a chip, NuHeart™, to identify and validate multiple drug pipelines rapidly as well as help us to determine biomarkers and stratify the patients for a clinical trial recruitments. Our precision heart failure pipelines are at least ten times more cost-effective to develop, especially during their clinical stages. Using our platform, we have developed two pipelines of small-molecule candidates for difficult to treat, genetically defined heart failure conditions. Our Pipelines of precision medicines have the potential to deliver better outcomes for patients fighting hard to treat heritable heart disease.
Collaborative patient-driven precision medicine-based drug development empowered with our novel platform will lead to meaningfully better outcomes for heart failure patients, which we refer to as InvivoSciences’ discovery engine to develop target therapies. Our lead program includes candidates in preclinical development for monogenetic heart failures. To date, IVS raised $8.5 Million non-dilutive funding from founders, board, commercial contracts, and grants. The funds have been used to create a portfolio of assets (breakthrough discovery platform, NuHeart™, three genetically defined disease models, current discovery programs, and a strong portfolio of patents including both US and international.
To join and support our drug discovery programs forward, InvivoSciences is seeking world-class life science investors and strategic partners for our Series A round for growth capital for $10 M in two trunches for commercial growth and accelerating our drug program.
InvivoSciences Inc.
CEOCliff Ansel
Respinova’s Pulsehaler™ technology is the first and only treatment to directly re-open the collapsed small airways of COPD patients, thereby reducing breathlessness and improving patient’s ability to walk. The technology was clinically proven in a clinical study, and published in the peer reviewed Journal of COPD. Our technology is protected by 6 patent families, with 15 issued patents and many additional pending patents.
Respinova’s technology pipeline also includes devices for improving delivery of inhaled drugs. This technology was clinically proven to deliver drugs more than 200% better than traditional nebulizers, with significant improvements in lung function. We have begun initial discussions with Pharma companies to partner in the development of Best-in-Class inhaled therapies, including COPD, Cystic Fibrosis, Asthma, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension.